Par Pharma suit + IMS ruling = off-label showdown?

October 19, 2011 | By Tracy Staton
Email LinkedIn
Tools

Par Pharmaceuticals' ($PRX) free speech lawsuit against the FDA--coupled with recent Supreme Court action--could prompt a court battle over off-label marketing. "Par's going to blow it wide open," the Coalition for Healthcare Communication's John Kamp tells Medical Marketing & Media. Report

Filed Under

,

Comments

Press Releases

Featured Jobs